Literature DB >> 12384533

UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1.

Qiang Yu1, JiHyun La Rose, Hongliang Zhang, Haruyuki Takemura, Kurt W Kohn, Yves Pommier.   

Abstract

UCN-01 (7-hydroxystaurosporine) is a cell-cycle checkpoint abrogator that sensitizes cells to ionizing radiation (IR) and chemotherapeutic agents. It has been shown previously that UCN-01 abrogates DNA-damage-induced G(2) checkpoint most selectively in p53-defective cells, by primarily targeting Chk1. Here we show that UCN-01 prevented IR-induced p53 up-regulation and p53 phosphorylation on serine 20, a site previously identified for Chk2 (or/and Chk1) kinase. We found that in human colon carcinoma HCT116 cells, IR treatment enhanced Chk2 kinase activity, whereas Chk1 activity remained unchanged, which suggested that UCN-01 may interrupt IR-induced p53 response by inhibiting Chk2 kinase. This conclusion is supported by in vitro kinase assays, showing that UCN-01 inhibits Chk2 immunoprecipitated from HCT116 cells (IC(50), approximately 10 nM). In addition, UCN-01 efficiently abrogated both the initiation and maintenance of IR-induced G(2) arrest in HCT116 cells and their isogenic p53 (-/-) derivative, indicating that G(2) checkpoint abrogation by UCN-01 is p53 independent. In the p53 (-/-) cells, there was no p21(Waf1/Cip1) induction nor UCN-01-induced apoptosis. Taken together, these observations indicate that UCN-01 can modulate both Chk1 and Chk2 in intact cells and enhance IR-induced apoptosis in p53-deficient, and consequently p21-deficient, cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384533

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Structural characterization of inhibitor complexes with checkpoint kinase 2 (Chk2), a drug target for cancer therapy.

Authors:  George T Lountos; Andrew G Jobson; Joseph E Tropea; Christopher R Self; Guangtao Zhang; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  J Struct Biol       Date:  2011-09-22       Impact factor: 2.867

2.  A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe.

Authors:  Oliver Riesterer; Fumihiko Matsumoto; Li Wang; Jessica Pickett; David Molkentine; Uma Giri; Luka Milas; Uma Raju
Journal:  Invest New Drugs       Date:  2009-12-22       Impact factor: 3.850

3.  p53-dependent G(1) arrest in 1st or 2nd cell cycle may protect human cancer cells from cell death after treatment with ionizing radiation and Chk1 inhibitors.

Authors:  L Petersen; G Hasvold; J Lukas; J Bartek; R G Syljuåsen
Journal:  Cell Prolif       Date:  2010-08       Impact factor: 6.831

4.  Biochemical assays for the discovery of TDP1 inhibitors.

Authors:  Christophe Marchand; Shar-yin N Huang; Thomas S Dexheimer; Wendy A Lea; Bryan T Mott; Adel Chergui; Alena Naumova; Andrew G Stephen; Andrew S Rosenthal; Ganesha Rai; Junko Murai; Rui Gao; David J Maloney; Ajit Jadhav; William L Jorgensen; Anton Simeonov; Yves Pommier
Journal:  Mol Cancer Ther       Date:  2014-07-14       Impact factor: 6.261

5.  Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.

Authors:  Ryan Montano; Injae Chung; Kristen M Garner; David Parry; Alan Eastman
Journal:  Mol Cancer Ther       Date:  2011-12-27       Impact factor: 6.261

6.  Crystal structure of checkpoint kinase 2 in complex with NSC 109555, a potent and selective inhibitor.

Authors:  George T Lountos; Joseph E Tropea; Di Zhang; Andrew G Jobson; Yves Pommier; Robert H Shoemaker; David S Waugh
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

Review 7.  Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy.

Authors:  Yingmei Wang; Ping Ji; Jinsong Liu; Russell R Broaddus; Fengxia Xue; Wei Zhang
Journal:  Mol Cancer       Date:  2009-02-13       Impact factor: 27.401

8.  Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.

Authors:  Feng Sun; Eli Chan; Zhenlong Wu; Xiaojing Yang; Victor E Marquez; Qiang Yu
Journal:  Mol Cancer Ther       Date:  2009-12       Impact factor: 6.261

9.  DNA damage mediated s and g(2) checkpoints in human embryonal carcinoma cells.

Authors:  XiaoQi Wang; Vincent C H Lui; Ronnie T P Poon; Ping Lu; Randy Y C Poon
Journal:  Stem Cells       Date:  2009-03       Impact factor: 6.277

10.  The ATR-Chk1 pathway plays a role in the generation of centrosome aberrations induced by Rad51C dysfunction.

Authors:  Mari Katsura; Takanori Tsuruga; Osamu Date; Takashi Yoshihara; Mari Ishida; Yoshitaka Tomoda; Miyuki Okajima; Motoki Takaku; Hitoshi Kurumizaka; Aiko Kinomura; Hiromu K Mishima; Kiyoshi Miyagawa
Journal:  Nucleic Acids Res       Date:  2009-04-29       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.